Skip to main content
Download PDF

Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Journal of Hematology & Oncology volume 14, Article number: 135 (2021) Cite this article

The Original Article was published on 09 August 2021

Correction to: J Hematol Oncol (2021) 14:121 https://doi.org/10.1186/s13045-021-01111-4

The original article [1] incorrectly states that OMO-1 is a MYC inhibitor in two instances: in the Direct MYC Inhibition sub-section of the MYC Inhibitors section, and in Table 3.

The authors wish to clarify that OMO-1 is not a MYC inhibitor, and its mentions in the original article should be disregarded.

Reference

  1. Ahmadi SE, et al. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol. 2021;14:121. https://doi.org/10.1186/s13045-021-01111-4.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

    Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi & Majid Safa

  2. Medical Laboratory Sciences Program, College of Health and Human Sciences, Northern Illinois University, DeKalb, IL, USA

    Rouzbeh Chegeni

  3. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran

    Majid Safa

Authors
  1. Seyed Esmaeil Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samira Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahman Zarandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rouzbeh Chegeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Majid Safa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rouzbeh Chegeni or Majid Safa.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmadi, S.E., Rahimi, S., Zarandi, B. et al. Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14, 135 (2021). https://doi.org/10.1186/s13045-021-01152-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13045-021-01152-9

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us